These biopharma stocks have great prospects and can be purchased today at attractive prices.
How does the genomic sequencing specialist stack up against Buffett's acquisition criteria?
The cancer-test maker reports solid third-quarter results on its way to breakeven.
The scientific-test maker registers a solid third quarter.
Today Invitae is a tiny, money-losing genetic testing company. But the future looks incredibly bright -- and it's arriving as we speak.
These three graphics show investors what they need to know about the genetic testing company.
There could be more problems in store for Illumina based on its disappointing sneak peek at Q3 revenue.
Shares drop in response to preliminary third-quarter results that came in well short of management's guidance.
The rumors of a $30 billion megamerger likely don’t hold water, but they could still point to some upside in gene-sequencing stocks.
Pacific Biosciences is growing more quickly than Illumina, which is struggling to overcome sluggish demand in Europe.